These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 17351748)
1. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study. Takeda K; Takifuji N; Negoro S; Furuse K; Nakamura S; Takada Y; Hoso T; Hayasaka S; Nakano T; Araki J; Senba H; Iwami F; Yamaji Y; Fukuoka M; Ikegami H Invest New Drugs; 2007 Aug; 25(4):377-83. PubMed ID: 17351748 [TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial. Sawa T; Yana T; Takada M; Sugiura T; Kudoh S; Kamei T; Isobe T; Yamamoto H; Yokota S; Katakami N; Tohda Y; Kawakami A; Nakanishi Y; Ariyoshi Y Invest New Drugs; 2006 Mar; 24(2):151-8. PubMed ID: 16502350 [TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer. Sugiura T; Ariyoshi Y; Negoro S; Nakamura S; Ikegami H; Takada M; Yana T; Fukuoka M Invest New Drugs; 2005 Aug; 23(4):331-7. PubMed ID: 16012792 [TBL] [Abstract][Full Text] [Related]
4. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401). Kaneda H; Okamoto I; Hayashi H; Yoshioka H; Miyazaki M; Kudoh S; Kimura T; Sugiura T; Sawa T; Takeda K; Iwamoto Y; Satouchi M; Akita K; Saito H; Goto I; Shibata K; Fukuoka M; Nakagawa K; J Thorac Oncol; 2010 Jan; 5(1):105-9. PubMed ID: 19884859 [TBL] [Abstract][Full Text] [Related]
5. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960 [TBL] [Abstract][Full Text] [Related]
6. Amrubicin monotherapy for elderly patients with previously treated lung cancer. Nakao M; Oguri T; Suzuki T; Kunii E; Tomita Y; Iwashima Y; Miyazaki M; Maeno K; Sato S; Ueda R Intern Med; 2010; 49(17):1857-62. PubMed ID: 20823645 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of amrubicin as a third or later line of chemotherapy for advanced non-small cell lung cancer. Igawa S; Sasaki J; Ishihara M; Otani S; Maki S; Hiyoshi Y; Kasajima M; Katono K; Takakura A; Masuda N Chemotherapy; 2013; 59(2):99-105. PubMed ID: 24021914 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Yana T; Negoro S; Takada M; Yokota S; Takada Y; Sugiura T; Yamamoto H; Sawa T; Kawahara M; Katakami N; Ariyoshi Y; Fukuoka M; Invest New Drugs; 2007 Jun; 25(3):253-8. PubMed ID: 17039404 [TBL] [Abstract][Full Text] [Related]
9. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K; J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301. Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K; J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694 [TBL] [Abstract][Full Text] [Related]
11. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities. Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172 [TBL] [Abstract][Full Text] [Related]
12. Phase II study of amrubicin at a dose of 45 mg/m2 in patients with previously treated small-cell lung cancer. Asao T; Nokihara H; Yoh K; Niho S; Goto K; Ohmatsu H; Kubota K; Yamamoto N; Sekine I; Kunitoh H; Fujiwara Y; Ohe Y Jpn J Clin Oncol; 2015 Oct; 45(10):941-6. PubMed ID: 26232449 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of oral topotecan in advanced non-small cell lung cancer. White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709 [TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer. Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702. Inoue A; Sugawara S; Maemondo M; Mori Y; Oizumi S; Harada M; Taima K; Morikawa N; Ishida T; Kinoshita I; Watanabe H; Suzuki T; Nakagawa T; Saito R; Nukiwa T Lung Cancer; 2015 Jul; 89(1):61-5. PubMed ID: 26004087 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer. Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980 [TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer. Otani S; Hamada A; Sasaki J; Wada M; Yamamoto M; Ryuge S; Takakura A; Fukui T; Yokoba M; Mitsufuji H; Toyooka I; Maki S; Kimura M; Hayashi N; Ishihara M; Kasajima M; Hiyoshi Y; Katono K; Asakuma M; Igawa S; Kubota M; Katagiri M; Saito H; Masuda N Am J Clin Oncol; 2015 Aug; 38(4):405-10. PubMed ID: 26214085 [TBL] [Abstract][Full Text] [Related]
19. Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small cell lung cancer. Yoshimura N; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Ichimaru Y; Hirata K; Kudoh S Am J Clin Oncol; 2013 Apr; 36(2):105-9. PubMed ID: 22270109 [TBL] [Abstract][Full Text] [Related]
20. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S; Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]